New Weight Loss Drugs: Impressive Results, Hefty Price Tags, and Accessibility Concerns

Boston, Massachusetts United States of America
Healthy lifestyle, including regular exercise and balanced diet, remains the most effective approach for managing weight and overall health.
High cost of these medications raises concerns among doctors and health experts about accessibility.
These drugs have shown impressive results in helping people lose weight but come with hefty price tags.
The US market for obesity treatments is projected to see a surge of new drug launches between 2024 and 2028, with Novo Nordisk expected to account for six of these launches.
Two new weight loss drugs, GLP-1 agonists, have been approved and commercialized: Wegovy and Ozempic by Novo Nordisk, Mounjaro and Zepbound by Eli Lilly.
New Weight Loss Drugs: Impressive Results, Hefty Price Tags, and Accessibility Concerns

Two recent developments in the world of weight loss treatments have generated significant buzz: the approval and commercialization of GLP-1 agonists for weight loss, such as Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Mounjaro and Zepbound. These drugs have shown impressive results in helping people lose weight, but they also come with a hefty price tag.

According to data from GlobalData, the US market for obesity treatments is projected to see a surge of new drug launches between 2024 and 2028. Novo Nordisk alone is expected to account for six of these launches, with its pipeline drug Cagrisema (semaglutide cagrilintide).

However, the high cost of these medications has raised concerns among doctors and health experts. Dr. Lauren Eberly, a cardiologist and health services researcher at the University of Pennsylvania, expressed her concern that patients with a disproportionate burden of disease are less likely to get access to these medicines due to their cost.

It is important to note that while these drugs can aid in weight loss, they should not be seen as a magic bullet. A healthy lifestyle, including regular exercise and a balanced diet, remains the most effective approach for managing weight and overall health.

The obesity population in the US is approaching 75%, with one in three American adults being prediabetic. The prevalence of chronic illnesses and disabilities associated with obesity, such as type 2 diabetes, cardiovascular diseases, autoimmune diseases, joint diseases, respiratory diseases, sleep-related disorders, and neoplastic (cancer) diseases is a major concern.

The healthcare system must find ways to make these treatments more accessible and affordable for all patients. In the meantime, focusing on lifestyle changes remains the most effective strategy for managing weight and overall health.


Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image

Confidence

91%

Doubts
  • Are there any potential side effects of these new weight loss drugs that were not mentioned in the article?
  • What is the exact cost of these medications and how does it compare to other obesity treatments?

Sources

98%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Weight loss drugs and the many use cases in medical treatments

Yahoo Finance Julie Hyman Sunday, 21 April 2024 07:23
  • Unique Points
    • Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Zepbound are leading weight loss drugs in the latest GLP-1 cycle.
    • Wegovy is approved for heart treatment in addition to weight loss.
    • Ozempic is in clinical trials for kidney treatment for those with diabetes and who are overweight.
    • Zepbound has sleep apnea benefits, making it a weight loss-only drug from Eli Lilly.
  • Accuracy
    • Novo Nordisk's Ozempic and Wegovy, and Eli Lilly’s Zepbound are leading weight loss drugs in the latest GLP-1 cycle.
    • ,
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

94%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

How 'miracle' weight-loss drugs made health disparities worse

The Los Angeles Times Karen Kaplan Monday, 15 April 2024 10:00
  • Unique Points
    • Doctors who treat obesity fear these medications may worsen health disparities due to their high cost.
    • Dr. Lauren Eberly, a cardiologist and health services researcher at the University of Pennsylvania, expressed concern that patients with a disproportionate burden of disease are less likely to get access to these medicines.
  • Accuracy
    • The American Heart Association, Oprah Winfrey, and Science magazine have praised the weight-loss drugs Ozempic, Wegovy, Mounjaro, and Zepbound as game changers and breakthroughs.
    • These medications are approved by the Food and Drug Administration to help people with Type 2 diabetes control their blood sugar levels and reduce the risk of cardiovascular problems.
    • Ozempic has a list price of $968.52 for a 28-day supply, Wegovy costs $1,349.02 every four weeks, Mounjaro is priced at $1,069.08 for 28 days of medicine, and Zepbound has a list price of $1,059.87 per 28 days.
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (95%)
    The author makes an appeal to authority by quoting the American Heart Assn., Oprah Winfrey, Science magazine, and Dr. Lauren Eberly. However, this does not constitute a fallacy as long as the author is accurately reporting their statements and not endorsing them herself.
    • ] The American Heart Assn. calls them ['game changers']. [
    • Oprah Winfrey says they're 'a gift'.
    • Science magazine anointed them the '2023 Breakthrough of the Year.'
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

97%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

US to see surge in new obesity drug launches in next five years

Biopharma-Reporter Unknown biopharma-reporter.com Tuesday, 16 April 2024 00:00
  • Unique Points
    • GlobalData projects the release of 13 new obesity drugs in the US between 2024 and 2028, representing a significant increase from the three launches in the preceding five-year period.
    • Novo Nordisk is expected to account for six of these projected launches with its pipeline drug Cagrisema (semaglutide + cagrilintide), forecasted to generate $7.4 billion by 2029.
  • Accuracy
    • Two blockbuster obesity drugs, Wegovy (semaglutide) by Novo Nordisk and Mounjaro (tirzepatide) by Eli Lilly, generated $9.7 billion globally in 2023.
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (95%)
    No formal fallacies found. However, there are some implicit assumptions and inflammatory rhetoric.
    • . . . companies are racing to commercialize their alternative obesity treatments, as a prodigious 13 drug launches are projected over the next five years in the US, according to data and analytics firm GlobalData.
    • In the U.S., obesity rates rose from 31% in 1999 to 42% in 2020 and this trajectory is forecast to continue, as nearly 50% of US adults are expected to be obese by 2030.
    • According to GlobalData, Novo Nordisk will account for six of the estimated 13 launches . . .
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

81%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Want to slim down? Change your lifestyle, not your medication | GUEST COMMENTARY

The Baltimore Sun David Sherer Sunday, 14 April 2024 10:00
  • Unique Points
    • The prevalence of individuals who are either overweight or obese in the US is approaching 75%.
    • One in three American adults is prediabetic and about 80% of them are unaware of it.
  • Accuracy
    • About 20% of Americans take five or more prescription medications, with about 85% taking at least one prescription medication.
  • Deception (30%)
    The article by David Sherer contains several instances of deception through selective reporting and emotional manipulation. The author presents a biased view against weight loss medications while ignoring the benefits they can provide for certain individuals, particularly those with co-existing cardiovascular illnesses. He also uses fear tactics to manipulate readers' emotions by exaggerating the risks associated with these medications without providing proper context or citing reliable sources.
    • In patients who desire to lose a small or moderate amount of weight, is it really worth the risks that have emerged in recent studies?
    • The coming shortage of doctors and nurses, along with spiraling health care spending, will force us to a reckoning that will shock many in the near future.
    • There have been reports, such as the one from October published in the Journal of the American Medical Association from The University of British Columbia. It linked GLP-1 agonists (Monjauro and Zepbound are in this class) to a nine times higher incidence of pancreatitis, an over four times the risk of bowel obstruction and a 3.67 times the risk of gastroparesis (stomach paralysis) when compared to using weight loss treatment bupropion and naltrexone.
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (95%)
    The author expresses a clear bias against the use of medication for weight loss and in favor of lifestyle changes. He uses strong language to criticize the use of medication, referring to it as a 'crutch' and implying that it is not effective in the long term. He also implies that those who take medication for weight loss are making poor choices and contributing to the strain on the healthcare system.
    • But do we really know the long-term ramifications of these agents? What does the science show?
      • The coming shortage of doctors and nurses, along with spiraling health care spending, will force us to a reckoning that will shock many in the near future.
        • Yet we cling to medications, instead of lifestyle changes, for the answer to our ills.
        • Site Conflicts Of Interest (100%)
          None Found At Time Of Publication
        • Author Conflicts Of Interest (100%)
          None Found At Time Of Publication